Pseudomonas aeruginosa, known as one of the leading causes of morbidity and mortality in cystic fibrosis (CF) patients, secretes a variety of virulence-associated proteases. These enzymes have been shown to contribute significantly to P. aeruginosa pathogenesis and biofilm formation in the chronic colonization of CF patient lungs, as well as playing a role in infections of the cornea, burn wounds and chronic wounds. Our lab has previously characterized a secreted P. aeruginosa peptidase, PaAP, that is highly expressed in chronic CF isolates. This leucine aminopeptidase is not only secreted solubly, it also associates with bacterial outer membrane vesicles (OMVs), structures known for their contribution to virulence mechanisms in a variety of Gram-negative species and one of the major components of the biofilm matrix. With this in mind, we hypothesized that PaAP may play a role in P. aeruginosa biofilm formation. Using a lung epithelial cell/bacterial biofilm coculture model, we show that PaAP deletion in a clinical P. aeruginosa background leads to increased early biofilm formation. We additionally found that only native vesicle-bound PaAP, as opposed to its soluble forms, could reconstitute the original PaAP-mediated inhibition phenotype, and that the PaAP-containing vesicles could disperse preformed biofilm microcolonies of Klebsiella pneumoniae, another lung pathogen. These data provide the basis for future work into the mechanism behind PaAP-OMV mediated bacterial microcolony dispersal and the application of these findings to clinical anti-biofilm research.
Introduction
The Gram-negative bacterium Pseudomonas aeruginosa is a prominent opportunistic pathogen capable of causing both acute and chronic disease in a variety of compromised hosts. P. aeruginosa is most well known as a leading cause of morbidity and mortality in cystic fibrosis (CF) patients 1 . In these individuals, the pathogen establishes chronic, biofilm-based infections that may persist for decades in the unique, mucous-rich environment of the CF lung. In addition to lung tissue, P. aeruginosa forms biofilms on a wide range of substrates relevant to human infection, including corneal and skin tissue, as well as soil and water reservoirs and hospital surfaces, which can contribute to infection initiation and spread 2 . P. aeruginosa is considered a model organism for the study of biofilm formation, and many of the cellular and matrix components contributing to this mode of growth have been studied previously [3] [4] [5] . The process of forming biofilm communities has also been characterized, revealing distinct growth phases. First the bacteria settle and attach onto a suitable host tissue or abiotic surface, then they begin to form stationary microcolonies and secrete extrapolymeric substance (EPS) to form a dense matrix. This matrix contains a variety of polysaccharides, as well as proteins, lipids, OMVs, and eDNA 4, 6 ; however, the mechanisms by which many of these secreted bacterial components specifically affect microcolony growth and development remain unclear.
As with other extracellular pathogens, P. aeruginosa secretes many of its virulence determinants into the extracellular milieu to affect interactions with the host, including those in the biofilm matrix. Interestingly, many of the virulence factors secreted specifically by P. aeruginosa demonstrate proteolytic activities [7] [8] [9] . These enzymes, including elastase, protease IV, and alkaline protease, act on both bacterial and host proteins to directly impact hostpathogen interactions. For example, purified elastase has been found to cleave fibrin, laminin, various immunoglobulins, and components of the complement system 10 . This activity not only interferes with host defense mechanisms but may also impact host epithelial junctions, allowing the bacteria entrance to otherwise inaccessible tissues. These proteases can additionally aid in biofilm formation and antibiotic resistance 11 . Based on the importance of known virulenceassociated, secreted proteases in P. aeruginosa biofilm formation, it follows that other proteases in the secretome, many of which have not been fully characterized, may also play a role in these processes.
With the goal of identifying factors that may contribute to chronic infections, our lab compared secretome protein expression profiles of clinical P. aeruginosa isolates from chronically infected CF patients to those of highly passaged laboratory and environmental strains. Several proteins were identified as being more highly expressed in all the clinical strains, indicating their potential involvement in virulence and chronic infection mechanisms.
Among the proteins identified was aminopeptidase PA2939, known as PaAP (Pseudomonas aeruginosa aminopeptidase) 12 .
Cahan et al. first described the proteolytic activity of PaAP in P. aeruginosa supernatants and classified it as a leucine aminopeptidase and a member of the M28 family of metalloproteases 9 . PaAP expression is regulated through quorum sensing (QS) mechanisms, and the protein is secreted via the Pseudomonas type II Xcp secretion pathway 13 . Initially, PaAP enters the extracellular environment as a 536 amino acid proenzyme. It is then processed by a variety of extracellular proteases at the C terminus to activate its enzymatic activity, and finally undergoes auto-processing at its N-terminus to create a 56 kDa, enzymatically active product 14 .
It can be further processed extracellularly into several smaller, active products ranging from 55 kDa to 26 kDa. Outside of the cell, PaAP is found both soluble in the extracellular environment and as an abundant component of outer membrane vesicles (OMVs) 12 .
OMVs are formed from the envelope of Gram-negative bacteria and are small, discrete extracellular structures containing distinct membrane protein, lipid, and soluble periplasmic content 15 . They are known to interact with the external environment, including host tissues 16 .
Vesicles produced by many Gram-negative pathogens, including P. aeruginosa, can elicit host immune responses, and many also serve as delivery mechanisms for bacterial virulence factors 16 . Of particular importance to our studies, OMVs have been implicated in the process of biofilm formation 6, 15, 17 . Schooling et al. demonstrated that OMVs are present in P. aeruginosa biofilm matrix and that bacteria in biofilms exhibit higher OMV production rates as compared to planktonic cells 18 . When these biofilm-derived vesicles were analyzed, PaAP was found to be one of the most abundant proteins 19 .
Bacterial density, as communicated through quorum sensing, is known to be an important regulatory facet of biofilm development 20 . Not only is PaAP expression regulated by quorum sensing, the XCP type II secretion system that secretes PaAP is also QS-regulated 13 . In addition, when P. aeruginosa was cultured on host epithelial cells, PaAP expression was found to increase significantly 21 suggesting that PaAP may play a role in biofilm formation on the host cells. Together, these data suggest PaAP's potential role in fine-tuned pathogenesis processes, including biofilm formation and infection.
In this study, we report on the role of the secreted P. aeruginosa leucine aminopeptidase on biofilms formed on both abiotic and host cellular substrates. Using a coculture model in which single-species bacterial biofilms are formed on a confluent layer of host cells, we show that PaAP expression inhibits the formation of early biofilms on lung epithelial cells. Additionally, we characterize microcolony architecture and the vesicular components required for PaAP's inhibitory activity against coculture biofilms. Finally, we investigate the broad impact of the PaAP-containing OMVs on biofilm development by non-self bacteria. These data provide novel insight into how the P. aeruginosa aminopeptidase can modulate clinically-relevant bacterial biofilms.
Materials and Methods
Bacterial strains and cell culture methods P. aeruginosa strains used include the laboratory strain PAO1 (Pf1 phage-cured from our lab collection) and minimally passaged, non-mucoid cystic fibrosis clinical isolates CF2, CF3, and S470 as well as the previously-described isogenic mutants 12, 22 . To generate fluorescent strains, we transformed bacteria with the dTomato expression plasmid, p67T1 23 . Klebsiella pneumoniae strain 43816 was obtained from ATCC. A549 human lung epithelia carcinoma cells (ATCC CCL-185) were grown in F-12K media containing 10% fetal bovine serum plus penicillin/streptomycin/fungizone. Unless specifically mentioned, all reagents were obtained from Sigma-Aldrich.
Abiotic biofilm quantitation
Bacterial cultures were grown overnight in LB (Luria Broth (MILLER), Millipore-Sigma) (37°C, 200 rpm) with antibiotics if appropriate. The cultures were vortexed for 15 sec and diluted 1:1000 in M63 minimal media (supplemented with 1 mM magnesium sulfate, 0.2% glucose, and 0.5% casamino acids as outlined previously 24 ) with no antibiotics. Aliquots of the diluted culture (100 mL/well) were incubated in five 96-well flat bottom polystyrene dishes (VWR) for 0, 2, 6, 10, or 24 h at 37°C with no shaking and evaluated using a static biofilm quantitation assay 24 .
Briefly, at the incubation endpoint, the plate was washed out using distilled water (dH 2 0). After three washes, 150 mL of 1% aqueous Crystal Violet solution was added to each well and the samples were incubated for 10 min at room temperature. The stained wells were washed three times using dH 2 0, 200 mL of 30% aqueous acetic acid was added to solubilize the dye, and the OD 495 was measured.
Abiotic biofilm imaging
Glass coverslips were placed in 12-well polystyrene dishes (VWR) at an angle and sterilized with a UV light for 20 min. Bacterial cultures were grown (overnight, shaking, 37°C) in LB containing the appropriate antibiotics. Cultures were vortexed for 15 sec and diluted 1:1000 in M63 minimal media with no antibiotics. A portion (1 mL) was added to each well of the 12-well dish containing the coverslips, and the cultures were incubated for 5 or 24 h, without shaking at 37°C. The coverslips were removed from the cultures and briefly rinsed in dH 2 0. The coverslips were then mounted on glass slides and the biofilm structures examined using a Zeiss 780 inverted confocal microscope. Biomass was calculated using Comstat 2.1.
qRT-PCR
Abiotic or coculture biofilms were grown for the indicated times as described. For coculture biofilms, supernatants were removed and 1 mL of Trizol was added to each sample to lyse both bacterial and A549 cells. For abiotic biofilms, 3 mL/well of cultures incubated in 6-well polystyrene dishes (VWR) were used to obtain sufficient biofilm material for analysis over the given time course. These samples were pipetted extensively to partially homogenize them and transferred to 15 mL conical tubes, in which the bacteria were pelleted. Trizol (1 mL, Invitrogen) was used to lyse each sample. A standard Trizol extraction was performed as described by the Invitrogen protocol, and RNA was extracted from the aqueous phase. The RNA was The bacterial samples were diluted in F-12K media (without antibiotic/antimycotic) and added to the A549-containing wells at MOI 30. The cocultures were incubated for 1h (37°C, 5% CO 2 ) to allow the bacteria to attach to the cell surface. The cocultures were then washed three times with sterile PBS, and the media was replaced with F-12K containing 0.4% L-arginine. The cultures were incubated for an additional 4 h at 37°C and the media was replaced with microscopy-grade media (Sigma DMEM without Phenol Red, supplemented with 0.4% arginine). Images were taken on a Zeiss 780 inverted confocal microscope. Biomass calculations were completed using Comstat 2.1, and 3D colony models were created using the 3D viewer plugin for Image J. This protocol was adapted from previously published work 26 .
Congo Red staining
To stain the biofilm extrapolymeric substance, a 100X Congo Red solution was made at 5 mg/mL in sterile PBS. The solution was sterile-filtered through a 0.22 mm PVDF syringe filter (VWR). Media on the biofilm cocultures to be stained was replaced with 1 mL of microscopygrade media (Sigma DMEM without Phenol Red, supplemented with 0.4% arginine), and the Congo Red solution was added to a final concentration of 50 mg/mL. The samples were incubated at 37°C for 10 min, the staining media was removed, the samples were washed twice with PBS, and the media was replaced with fresh microscopy-grade DMEM (Sigma DMEM without Phenol Red, supplemented with 0.4% arginine). Microscopy images were then taken on a Zeiss 780 inverted confocal microscope. Biomass calculations were completed using Comstat 2.1.
OMV isolation and supernatant fractionation
Bacterial cultures were grown overnight in LB at 37°C, diluted 1:100 into 1.5 L LB, and grown (37°C, shaking) to OD 600 0.9-1.1. Cells were pelleted (10,000xg for 15 min 4°C), and supernatants were collected and concentrated to 100 mL using tangential flow with a 10 kDa MWCO filter (Pall removed from the top in 1 mL aliquots, and the lipid and protein content for each fraction were identified using FM4-64 and Bradford assays as described previously 27 . The OMV-containing fractions (typically 1-5) and soluble protein fractions (typically 7-12) were pooled and diluted with HEPES, then centrifuged at 40,000xg for 2 h to pellet OMVs and proteins and to remove
Optiprep. Protein and OMV pellets were resuspended in HEPES, and sterile-filtered (0.4 mm PVDF, VWR).
rPaAP purification
rPaAP expression, purification, and refolding were carried out as described previously 14 , and the refolded protein was concentrated using 10,000 MWCO Amicon filter units (Millipore-Sigma).
The concentrated material was then dialyzed using the same method described above, applied to a S200 Sephadex ion exchange column, eluted with a gradient of 0-2 M NaCl, pH 7.6, at a flow rate of 0.02 mL/min, and 18-2 mL fractions were collected. Fractions were assayed for leucine aminopeptidase activity as described 28 , and analyzed by SDS-PAGE and Ruby staining as described above. Fractions containing pure rPaAP were pooled and concentrated using Amicon 10,000 MWCO filter units to ~0.5 mg/mL.
Complementation and dispersion experiments
For biofilm complementation assays, CFS, OMV fractions, soluble fractions, and rPaAP samples were prepared as described above, total protein was measured by Bradford assay, and aminopeptidase activity was measured as described above. 
Statistics
For all experiments, statistics were completed using GraphPad Prism t-tests unless otherwise indicated. For microscopy images and imaging quantifications, representative results are shown.
Results

Leucine aminopeptidase expression does not affect biofilm formation on abiotic substrates
Based on previous reports describing the high expression of the P. aeruginosa aminopeptidase PaAP in both late-log phase and biofilm cultures, as well as the involvement of OMVs in the biofilm matrix, we wanted to determine whether the presence of PaAP was critical to biofilm formation. Several stages are observed during the process of P. aeruginosa biofilm growth and development. Bacteria initially attach to the substrate, then a variety of matrix components, including polysaccharides, proteins and eDNA, interconnect the microcolony structure, generating protection from environmental and immune stresses. As the microcolonies mature, bacterial cells disengage from the structure, to disperse and colonize in new environments 29 . When grown in liquid media, P. aeruginosa forms biofilm communities called pellicles at the air-liquid interface. As the bacteria attach to the culture container, this abiotic biofilm development can be quantitatively assessed using a Crystal Violet stain 24 .
To examine the effect of PaAP on P. aeruginosa pellicle growth, we compared a clinical isolate (S470 WT) that our lab previously found to exhibit high constitutive levels of PaAP expression, with the previously described isogenic knockout strain (S470 ∆PaAP) that contains a disruption of PA2939, the gene encoding PaAP 22 . Cultures of both strains were grown statically in 96-well dishes, and biofilm density was determined at various time points. We monitored growth up to 24 h when the biomass decreased, consistent with other static biofilm models of P. aeruginosa 24 . No significant differences were seen in the biofilms at any of the time points ( Fig 1A) suggesting PaAP does not play a role in pellicle formation or stability.
Because the Crystal Violet assay only measures cell density and not differences in biofilm structure, microcolony biomass and organization were also assessed by microscopy of pellicle biofilms using S470 WT and S470 ∆PaAP strains expressing the cytoplasmic fluorescent protein dTomato. These strains were grown in 12-well dishes containing glass coverslips inserted at an angle. Biofilms formed at the air-liquid interface attached to the coverslips and were examined using confocal laser scanning microscopy (CLSM). Qualitative examination of the microscopy images showed no differences between the strains with regards to the overall structure of the biofilms or organization of the microcolonies (Fig 1C) . Total biovolumes for each image stack were calculated and the data confirmed that there were no significant differences between the wild type and PaAP-deficient strains (Fig 1D) .
To confirm that the lack of a difference in biofilm phenotype observed in the above assays was not simply due to a lack of PaAP expression, PaAP RNA levels were measured in the static cultures of S470 WT and S470 ∆PaAP at 6 h and 24 h post infection (hpi) using qRT-PCR. As expected, the WT strains showed PaAP expression in the biofilms (Fig 1B) , while the ∆PaAP S470 negative control did not (data not shown). Together, these data suggest that PaAP deletion does not impact the bacteria's ability to develop a biofilm on abiotic substrates or at the air-liquid interface under our experimental conditions.
P. aeruginosa early biofilm growth and microcolony organization on host epithelial cells is inhibited by PaAP expression
While PaAP did not affect the formation or architecture of P. aeruginosa biofilms on abiotic surfaces, we wanted to investigate whether PaAP affects biofilm formation on a live host cellular substrate as would be seen during P. aeruginosa acute or chronic respiratory infections.
When P. aeruginosa was cultured on host epithelial cells, in addition to a variety of virulenceassociated proteins, PaAP expression was found to increase significantly 27 , suggesting that PaAP may play a role in pathogenesis or biofilm formation on host cells. To assess differences in biotic biofilms, we adapted a previously developed biofilm coculture assay for use with A549 lung carcinoma cells 26 . When grown over the course of several days, these cells form fully confluent cell layers that partially model the polarized epithelial monolayers that the bacteria colonize during infection. Once grown to confluency they can be inoculated with bacteria and bacterial biofilm formation can be assessed by CLSM.
When confluent A549 cells were inoculated with the fluorescent S470 strain and incubated for up to 6 h, we noted significant damage to the A549 cells by 5 h, leading to breaks in the cell layer. This was consistent with the previously described toxicity of P. aeruginosa clinical strains to host cells 30 and established time courses for static coculture biofilm models 26 .
Once these cytotoxic bacteria infiltrated the host cell layer, the microcolony structure also broke down, as the bacteria were able to colonize the underlying tissue culture dish and migrate to the air-liquid interface. Thus, this cellular substrate could be used to investigate clinical P.
aeruginosa strain biofilm development only through the early stages (up to 5 h post bacterial infection) of microcolony formation.
We quantitatively compared coculture biofilms of fluorescent S470 WT and S470 ∆PaAP strains at 5 hpi, and we observed significant differences between the two biotic biofilms.
Surprisingly, the PaAP mutant strain formed biofilms with substantially greater cellular biomass compared to the WT strain (Fig 2A,B) . Not only were these differences statistically significant, they were also clearly visible by qualitative examination of the fluorescent biofilms. These data provided the first evidence that PaAP modulates early biofilm growth under conditions mimicking host infection.
To gain further insight into PaAP's effect on biofilms, we examined S470 WT and ∆PaAP microcolony morphologies (Fig 2D, E) . In addition to their greater quantitative biomass, S470
∆PaAP colonies appeared to display greater cellular organization. Even at this early point in biofilm development, characteristic mushroom-shaped colony structures were observed for the PaAP mutant. The S470 WT microcolonies, by comparison, showed very little cellular organization and were packed less densely. Based on these data, we can conclude that the lack of PaAP not only increases cellular biomass, but also cellular organization at the microcolony level during early coculture biofilm development.
To confirm this PaAP-dependent phenotype in a different strain background, we compared the biofilm characteristics of PAO1, a laboratory P. aeruginosa strain commonly studied in vitro, and the isogenic PAO1 ∆PaAP strain that harbors a transposon insertion in PA2939. We note that our lab previously showed that OMVs isolated from PAO1 cultures show very low aminopeptidase levels compared to S470 and other clinical P. aeruginosa isolates 12 .
Nevertheless, as with the clinical strain phenotype, PAO1 ∆PaAP formed significantly more biomass as compared to the WT counterpart (Fig 2A, C) . Our observations indicate that PaAP is important to biofilm development, even in strains with low endogenous PaAP expression, and that its role may be relevant to a broad range of P. aeruginosa strains.
Increased biofilm cellular density induced by PaAP deletion coincides with PaAP expression and increased EPS production
The results from the coculture assay in protocol to specifically label amyloid fibers and negatively charged extracellular polysaccharides in the P. aeruginosa matrix 31 . As shown in Fig 3 A and B , significantly higher levels of EPS staining were observed for S470 ∆PaAP cocultures than for the S470 WT counterpart. No staining was seen in the A549 cell-only controls. These data display the same trends observed for the S470 WT and ∆PaAP cellular biomass quantifications, supporting the discovery that PaAP expression prevents the formation of robust early biofilm structures.
There are several mechanisms through which PaAP may be able to affect the formation of early biofilms, including preventing efficient attachment of bacteria to the host cellular substrate and affecting colony growth post-attachment. To detail the time course of the PaAPdependent phenotype, we imaged the cocultures at hourly intervals post infection. Directly following the wash step at 1 hpi and up to 3 hpi, we observed a similar level of biomass from the S470 WT and ∆PaAP strains. A significant phenotype did not develop until 4 hpi (Fig 3C) ,
suggesting that the aminopeptidase functions to limit microcolony growth and development, rather than the initial steps of colonization and attachment.
Based on this timeline, it is expected that the observed phenotype developed in parallel with the level of aminopeptidase expression. Indeed, previous reports found PaAP to be regulated by the las quorum sensing system 13, 32 , and thus PaAP expression would be expected to increase as bacterial density increases in our experimental system. Using qRT-PCR, we examined the expression of PaAP in S470 WT biofilms over time under the coculture assay conditions. Consistent with quorum sensing density-dependent expression, our results show expression of PaAP mRNA at 1 hpi, increasing steadily over the next several hours (Fig 3D) .
Based on these data, it appears that the biofilm inhibition phenotype may depend on either a threshold level of aminopeptidase or a specific microcolony developmental phase.
Addition of PaAP-containing outer membrane vesicles, but not purified aminopeptidase, inhibits biofilm development by the PaAP deletion mutant
Based on its tightly-controlled, quorum sensing-regulated expression and secretion pathways, PA2939 complementation using plasmid-based expression has proven to be challenging and unfeasible; therefore, we performed biochemical complementation experiments.
Complementation was first tested using cell-free supernatants from mid-log phase cultures of S470 WT and S470 ∆PaAP. We confirmed the presence and activity of PaAP in the S470 WT supernatant and its absence in the S470 ∆PaAP supernatant by Western blot (Fig 4A) and aminopeptidase activity assays (data not shown). Equivalent amounts (by total protein) of the sterile supernatants, from S470 WT and ∆PaAP cultures were added to the cocultures of S470 ∆PaAP and A549 cells after the 1 hpi wash step, and incubated until the 5 hpi final imaging time point. Addition of the PaAP-containing S470 WT supernatant significantly decreased the bacterial biovolume in the coculture (Fig 4B) , while the S470 ∆PaAP supernatant had only minor qualitative effects on colony size and shape. These results provide strong evidence that secreted aminopeptidase is responsible for PaAP-dependent biofilm inhibition.
The ∆PaAP biofilms was assessed. Intriguingly, while the OMV-containing S470 WT fractions were able to significantly inhibit biofilm development by S470 ∆PaAP, the heavier, soluble aminopeptidase-containing fractions had no noticeable effect on biomass (Fig 4C) . Experiments using the different density fractions matched to aminopeptidase activity levels found in PaAP + OMVs yielded similar results (data not shown), confirming that, regardless of enzymatic activity, the soluble material was unable to inhibit biofilm growth. These data suggest that PaAPcontaining OMVs, but not soluble secreted aminopeptidase, inhibit early stages of biofilm development.
To further corroborate our finding that soluble forms of PaAP cannot prevent microcolony development, we purified and refolded recombinant P. aeruginosa aminopeptidase (rPaAP) expressed in E. coli 14 . The specific activity of this preparation was similar to, though slightly lower than, that of the native soluble enzyme purified from culture supernatants.
Equivalent amounts (by activity) of rPaAP and PaAP+ OMVs were added to the S470 ∆PaAP cocultures to test their ability to modulate biofilm formation. Consistent with the results using sPaAP, purified rPaAP was also incapable of disrupting the formation of robust biofilms by the ∆PaAP strain ( Fig 4D) .
We then hypothesized that addition of rPaAP or sPaAP may reconstitute the biofilm inhibitory activity of the OMVs isolated from ∆PaAP cultures (PaAP -OMVs). These rPaAP/PaAP -OMV and sPaAP/PaAP -OMV preparations had demonstrable aminopeptidase activity (data not shown), but the co-additions failed to inhibit biotic biofilm development by the S470 ∆PaAP strain (Fig 4D) . It may be that interactions between the aminopeptidase and the PaAP -OMVs were not natively reconstituted in our co-incubated preparations, as characteristics of rPaAP and sPaAP possibly prevent their interactions with OMVs. Nevertheless, these data suggest that native secretion and/or association with OMVs is critical for PaAP-dependent biofilm inhibition.
To explore which components of the vesicles were critical to PaAP + OMV-mediated biofilm inhibition, OMVs were treated to disrupt the native vesicle structure. These results are summarized in Table 1 . Treatment with Triton X-100 is expected to disrupt the lipid membrane structure and effectively liberate OMV cargo. Unexpectedly, detergent treatment significantly increased overall biofilm formation in both the S470 WT and ∆PaAP OMV-treated samples. It is unclear what caused this, as both soluble and insoluble factors could be liberated by detergent;
however, it prohibited us from assessing the effect of PaAP in a "burst vesicle" model.
To investigate if externally-localized protein is necessary for PaAP + OMV-mediated biofilm inhibition, we treated samples with a membrane impermeable enzyme, Proteinase K. We found that Proteinase K addition increased the leucine aminopeptidase activity of the vesicle samples. We note that this was not due to an off-target effect of Proteinase K on the aminopeptidase assay substrate, as an increase in cleaved substrate was not seen in any control samples, and sPaAP samples were fully degraded as expected (data not shown). Based on the mechanism of PaAP's extracellular processing and activation by other proteases 14 , it follows that increased aminopeptidase activity may be caused by partial Proteinase K cleavage of PaAP, leading to PaAP activation rather than expected degradation. This suggests that Proteinase K has partial access to the aminopeptidase to cause activation, leading us to conclude that it is not fully protected by the vesicle membrane. However, PaAP is protected from full degradation by its association with the vesicle, and anti-biofilm activity was not affected by the treatment.
In an attempt to eliminate full aminopeptidase and anti-biofilm activity from PaAP + OMVs, the vesicles were boiled at 95°C for 15 minutes. This treatment is expected to degrade all vesicular structures, membranes, and proteins; however, nearly one third of aminopeptidase activity and some anti-biofilm activity remained. A combination of boiling and Proteinase K further decreased aminopeptidase and anti-biofilm activity in the samples, but full degradation was not observed until the OMVs were treated with boiling, Triton X-100, and Proteinase K, which effectively liberated the aminopeptidase from any protective elements, allowing digestion.
The highly resistant nature of the aminopeptidase-vesicle association strengthens our conclusion that PaAP anti-biofilm activity is innately linked to native packaging into outer membrane vesicles. Additionally, the anti-biofilm activity of these particles directly paralleled their aminopeptidase activity, providing further evidence that PaAP mediates OMV anti-biofilm activity.
PaAP + OMVs disperse early P. aeruginosa and K. pneumoniae biofilms
Having determined that PaAP-containing OMVs are able to inhibit coculture biofilm formation, we were curious at what point in microcolony development these particles act. To investigate this, OMVs were added to cocultures either before inoculation (pre-treatment), at 1 hpi, or 0.5 h before the final imaging time point. Table 2 containing OMVs not only complemented the knockout phenotype, but the cellular biomass was virtually non-existent in these samples. To demonstrate that this phenotype was not specific to S470-derived vesicles, it was recapitulated with PAO1-derived OMV treatment of A549/S470 ∆PaAP cocultures. This treatment also led to biofilm dispersion; however, consistent with lower aminopeptidase expression by the PAO1 strain, PAO1 WT OMVs dispersed S470 ∆PaAP biofilms to a much lesser extent (Fig 5A) . Taken together, these experiments provide evidence that OMV-associated PaAP is able to disrupt microcolonies already formed on biotic substrates in addition to inhibiting their formation.
To further characterize the biofilm modulatory capabilities of PaAP-containing OMVs, we also tested their ability to inhibit or disperse biofilms grown on abiotic substrates in multi-well dishes. Equal amounts (by protein) of S470 WT and ∆PaAP OMV preparations were added to S470 ∆PaAP strains either during inoculation of the static cultures or 0.5 h prior to staining. At 2, 6, and 24 hpi, biofilm formation was assessed using a Crystal Violet stain. As shown in Fig 5B, no significant difference was seen between the untreated controls and the vesicle-treated biofilms in either the inhibition or dispersion Crystal Violet experiments. It should be noted that these results were not surprising, considering the lack of phenotypic differences between the wild type and the PaAP mutant using the abiotic biofilm assay.
During infections, such as occur in the lungs of CF patients, biofilms are often found as polymicrobial communities. As such, components secreted by one species can impact the microcolonies of other strains or species in nearby environments. Thus far, we have shown that PaAP + OMVs prevent and disperse biofilms of P. aeruginosa. To test if they could also exhibit cross-species effects, A549 cell layers were inoculated with K. pneumoniae, a bacterium which is often found with P. aeruginosa in cases of ventilator-associated pneumonia 33 These data suggest that the OMV-associated P. aeruginosa aminopeptidase not only acts to disrupt a process that is critical to the development of coculture biofilms by P. aeruginosa, but also that it has the ability to impact the growth and development of another clinically relevant pathogen.
Discussion
We set out to investigate the role of the PaAP leucine aminopeptidase in biofilm development, as PaAP is one of the most abundant proteins in the P. aeruginosa biofilm extracellular matrix and one of the major protein components of OMVs from clinical P.
aeruginosa isolates 12, 19 . In this study, we have shown that deletion of the PaAP-encoding gene did not affect the ability of clinical or laboratory P. aeruginosa strains to form biofilms on a polystyrene surface. However, when the bacteria were grown on a host cellular substrate, the absence of PaAP significantly increased cellular and matrix biomass, as well as microcolony density and organization. We discovered that the addition of the OMV-containing fractions of wild type bacterial culture supernatants could reduce biofilm formation by the mutant bacteria.
Further, we showed that purified OMVs from PaAP-expressing strains not only were able to inhibit the formation of early biofilms of PaAP-deficient P. aeruginosa, but they could also disperse biofilms that had reached early levels of maturity. Their inhibitory activity was highly resistant to degradation, and neither high density fractions containing native soluble active aminopeptidase, nor purified active recombinant PaAP, nor a mixture of aminopeptidase with PaAP -OMVs exhibited these inhibition and dispersion properties. These results suggest that not only PaAP, but also the native vesicle context of PaAP, is critical to exert this behavior. Finally, we provided evidence that PaAP-containing OMVs could disperse coculture biofilms of heterologous bacterial species, specifically, pre-formed K. pneumoniae biofilm microcolonies.
Our work supports a hypothetical mechanism in which the aminopeptidase and the native vesicle structure function synergistically to target bacterial microcolonies forming on host cells, aiding in biofilm inhibition and dispersion. 35 ). For the data presented in this report, biofilms were grown in M63 minimal media supplemented with casamino acids and glucose; however, we note that we also compared abiotic biofilms of WT and mutant strains grown in LB, LB/glycerol, and A549 cell culture media, with no observed differences in phenotype (data not shown). Combined with the difference in growth temperature, these nutritional differences would substantially impact the metabolic profile of the biofilm bacteria and reveal the distinct role of PaAP under Zhao's experimental conditions. In those assays, PaAP's activity is likely required for bacterial growth due to its ability to generate amino acid-based carbon sources. Indeed, they discovered that during late growth phases, the absence of PaAP led to death and lysis of P. aeruginosa. Consequent to lysis, the cells released a periplasmic enzyme, PslG, that enabled biofilm matrix digestion, a mechanism that is likely used in the environment to liberate bacteria so that they can reach a more nutrient-rich niche. By contrast, in our assay conditions the growth and death phases of WT and ∆PaAP cultures were indistinguishable (Fig 1A) . In sum, the mechanistic role for PaAP in P. aeruginosa biofilm modulation described in these two studies appear to be substantially different: in one, PaAP activity prevents starvation during nutrient deprivation and prevents the otherwise deathdependent release of an abiotic biofilm-degrading intracellular enzyme, and in the other, a form of the secreted aminopeptidase has a biotic biofilm inhibiting and degrading activity.
Since PaAP was known to exist in two enzymatically active secreted states, OMV-bound and soluble, we were curious whether one or both were active in dispersing biofilms. The light density OMV-containing fraction, but not the heavier sPaAP-containing fraction of the cell free supernatant of WT P. aeruginosa was found to harbor the early biofilm inhibitory activity. In addition, the combination of rPaAP to ∆PaAP OMVs failed to inhibit or disperse S470 ∆PaAP biofilms. These data suggested that subtleties of native vesicle packaging were critical, potentially by impacting PaAP orientation or association within the vesicle and vesicle-mediated delivery to the biofilm matrix. While future work will be required to determine PaAP's localization with regard to the vesicle structure, preliminary data from our lab, along with the fact that PaAP is known to be secreted through the OM, suggest that during OMV biogenesis the aminopeptidase localizes to the surface of OMVs 22 .
The inability of PaAP + OMVs to affect biofilms grown under our abiotic experimental conditions while dispersing partially maturing coculture biofilms of both pseudomonads and nonpseudomonads generated some further insight into the dispersal mechanism. The data do not favor the possibility that the differences in biofilms generated by the wild type and mutant bacteria are dependent on differences in host-derived biofilm factors secreted differentlially in response to the two bacterial strains. First, there is no significant difference in cytokine expression responses elicited for incubations with the S470 WT and ∆PaAP bacteria (data not shown), and second, the WT OMVs are active towards pre-initiated ∆PaAP mutant bacterial biofilms. Further, as we also observed activity against non-pseudomonas biofilms, it appears that the factor targeted by the PaAP + OMVs is a generally conserved feature of bacterial biotic biofilms. Together, these data lead us to favor a model whereby PaAP + OMV-mediated biofilm dispersal relies on targeting a factor (or factors) governing biofilm integrity that is either conserved and host cell-derived or conserved and host cell-elicited, but bacterially-derived, which would be consistent with the activity of many anti-biofilm enzymes against the biofilm matrix 36 .
Our data addressing the timing of PaAP + OMV-mediated biofilm dispersal support the following model, which outlines OMV interactions during the microcolony development stages observed in our coculture experiments (Fig 6) . The structural differences between these phases directly impact the mechanism by which PaAP + OMVs can access and disperse biofilms.
Pretreatment of the A549 host cell layer did not affect initial bacterial attachment, suggesting that direct PaAP + OMV-host cell interactions likely are not responsible for the observed dispersal phenotype. Rather, PaAP + OMVs demonstrated anti-biofilm activity at late stages of coculture infection, at which point they likely have decreased access to the host cells and act to disperse a developing matrix structure and multi-cellular architecture. PaAP + OMV production induced by quorum sensing inside the biofilm by WT P. aeruginosa would exhibit biofilm inhibiting activity at this point. Further, based on the ability of exogenously added PaAP + OMVs to disperse pre-formed P. aeruginosa and K. pneumoniae microcolonies, we note that released PaAP + vesicles can target and dissociate developing biotic microcolonies that they encounter in the environment. It is widely appreciated that OMVs can serve as vehicles to deliver bacterial toxins and effectors to host cells, and that adhesins localized to the surface of these OMVs may help target effector activity to specific host tissues 37 . Similarly, vesicles, which are known to be located within mature biofilm matrices, may help to direct the bioactive OMV cargo to these conserved microcolony and EPS structures.
Our data support the concept that increased PaAP expression observed in the clinical CF isolates is functionally similar to decreased virulence factor expression, as it limits biofilms at early microcolony formation stages, possibly to promote a less acutely toxic, long-term biofilm infection. In addition, aminopeptidase expression and secretion would allow biofilm-restricted cells to disperse and inhabit new, and perhaps more attractive, environmental niches. Typically, proteins enriched in bacterial clinical isolates contribute positively to pathogenesis mechanisms and biofilms are known to contribute to resistant infections, so PaAP's ability to inhibit biofilm formation appears to deviate from this expectation. However, bacterial factors have been identified that can contribute to human disease in a counterintuitive fashion. Longitudinal studies that follow the progression of P. aeruginosa strains from early colonization through chronic infection have shown that the bacteria quickly evolve and adapt to the conditions found in the CF lung, and that many of the genetic changes seen in chronic P. aeruginosa strains function to decrease overall bacterial pathogenicity [32] [33] [34] . For example, mucA mutations, which downregulate the expression of virulence-associated type III secretion systems, are frequently observed 35, 36 . Additionally, researchers have found mutations that decrease quorum sensing and, notably for this discussion, biofilm formation 32, 33 . The attenuation of virulence mechanisms during infection allows pathogens such as P. aeruginosa the ability to thrive in the host by reducing the possibility of an overactive immune response or host cell death.
In summary, the data presented here demonstrate that deletion of the P. aeruginosa leucine aminopeptidase enhances early biofilm formation and microcolony development under infection-like conditions. We have also shown that this process is mediated by naturally secreted OMVs, and that exogenous addition of PaAP-containing OMVs is able to inhibit biofilm growth and disperse previously formed biofilm structures formed by both self and non-self bacterial species. Future studies will seek to determine not only the mechanism behind this activity, but also its potential clinical relevance. µg/mL Proteinase K, or boiling for 15 min at 95°C. Proteinase K and Triton X-100 treated samples were incubated at for 1 h at 37°C. Combinatory treatments were done in the indicated order. 2 Aminopeptidase activity levels (±SD) were measured post-treatment, and values were normalized to S470 WT OMV aminopeptidase activity. 3 OMV samples were added to S470 ∆PaAP biofilm cocultures 1 hpi and biomass was quantified 5 hpi.
Biomass was calculated relative to untreated S470 ∆PaAP cocultures (=: no significant increase; +: significant increase; -: significant decrease). The number of +/-quantifies the relative biomass differences (+/-: 5-25%; ++/--: 26-50%; +++/---: >50%). A549 cells were incubated with vesicles for 0.5 h before bacterial inoculation. 2 Samples were imaged at the indicated times and assessed for biomass. 3 Biomass is represented relative to the untreated S470 ∆PaAP controls for each experiment (=: no significant difference; +: significant increase; -: significant decrease). The number of +/-quantifies the relative biomass differences (+/-: 5-25%; ++/--: 25-50%; +++/---: >50%).
Figure 1:
Deletion of the PaAP aminopeptidase had no effect on the structure or biomass of abiotic biofilms (A) P. aeruginosa strains were grown in multi-well dishes for the indicated times and abiotic biofilms were quantified by Crystal Violet staining (OD 495 ). (S470 WT: light gray; S470 ∆PaAP: dark gray) (B) Relative mRNA expression in S470 WT biofilms grown for the indicated times was calculated from qRT-PCR data using the ∆∆C T method, with normalization to PaAP levels in planktonic S470 WT cultures. Pellicles formed by S470 WT or ∆PaAP (as indicated) on glass coverslips after 6 h of growth were imaged by confocal microscopy (C) and their biomass measured (D). For all experiments, n=3. *p<0.05; ns, not significant. Scale bars: 200 µm. 
